Bispecific antibodies have meaningfully expanded the therapeutic armentarium in multiple myeloma. Talquetamab is a CD3+ T cell redirecting antibody targeting GPRC5D, which is expressed on multiple mye

DataCite Commons2024-03-06 更新70

Transcriptome analysis of CHEK1 overexpression (AC or HC) VS control (A or H) and CHEK1 knockdown (AK_D or HK_D) VS control (AK or HK) in Mutiple Myeloma.

多发性骨髓瘤

CHEK1基因功能研究

Transcriptome sequencing was used to analyze changes in related signaling pathways and gene expression in Mutiple Myeloma cells when CHEK1 was overexptressed or knocked down. Examination of eight cel

NIAID Data Ecosystem30

SegPC-2021-dataset

医学图像分析

多发性骨髓瘤

SegPC-2021: Segmentation of Multiple Myeloma Plasma Cells in Microscopic Images

kaggle2021-05-02 更新70

IL-18-secreting multi-antigen targeting CAR T-cells eliminate antigen-low myeloma in an immunocompetent mouse model [in vitro]

多发性骨髓瘤

CART细胞工程

Multiple myeloma is a plasma cell malignancy that is currently incurable with conventional therapies. Following the success of CD19-targeted chimeric antigen receptor (CAR) T-cells in leukemia and lym

NIAID Data Ecosystem30